Clinical trial NCT00579384 (phase 2, status: completed)
Conditions: photosensitive epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: jnj-26489112, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or postmenopausal/surgically sterile females. Post-menopausal is defined as no
             menses for the 18 months prior to study start. If menses have ceased within 36 months
             of the start of this study, then plasma follicle stimulating hormone must be elevated
             to within a post-menopausal range at study screening

          -  Pre-menopausal surgically sterilized patients must have a negative beta chorionic
             gonadotropin pregnancy test at screening and at Day -2

          -  Women of childbearing potential may be enrolled when results of the reproductive
             toxicology studies become available, after review of that reproductive toxicology data
             and upon agreement of the Sponsor and Principal Investigator and the relevant local
             Ethics Committee, provided these women agree to utilize an acceptable method of birth
             control

          -  Body Mass Index (BMI) between 18.5 and 35 kg/m2 (inclusive)

          -  BMI= weight/height2

          -  Firm documented diagnosis of idiopathic, photosensitive epilepsy with a generalized
             photoparoxysmal EEG response

          -  A photosensitive range in response to intermittent photic stimulation equal to or
             greater than 4 points in at least one eye condition at screening

          -  All values for hematology, coagulation, chemistry, and urinalysis within clinically
             acceptable ranges as they would be for healthy subjects prior to administration of
             study drug

          -  Willing to adhere to the prohibitions and restrictions specified in this protocol

          -  Male patients who are not sterile and are unwilling to use condoms for the duration of
             the study, ensure that their partner practices contraception or refrain from sexual
             intercourse (and until 90 days after the last dose of study medication).

        Exclusion Criteria:

          -  History of liver or renal insufficiency

          -  significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic
             (except epilepsy and febrile seizures), hematologic, psychiatric, or metabolic
             disturbances.

          -  Pregnant or lactating female or female insufficiently protected against pregnancy (for
             female patients of childbearing potential, a negative pregnancy test must be obtained
             and double-barrier method of contraception must be used starting from screening,
             throughout the study until follow-up visit), contingent upon satisfactory review of
             reproductive toxicology study results, and upon agreement of the Principal
             Investigator, the Sponsor, and the local Ethics Committee).

          -  Male subjects who are not sterile and are unwilling to use condoms for the duration of
             the study, ensure that their partner practices contraception or refrain from sexual
             intercourse (and until 90 days after the last dose of study medication).

          -  Any serious illness other than epilepsy.

          -  History of progressive neurological disorder, including brain tumor, active central
             nervous system infection, demyelinating disease, degenerative or progressive CNS
             disease.

          -  Tonic-clonic seizure experienced in the 21-day period prior to Day 1 study drug dose
             administration (including Day -1).

          -  Use of herbal medication (including St. John's Wort, garlic extract and herbal teas)
             or mineral supplements within 14 days prior to study drug administration.

          -  Use of neuroleptics (typical or atypical) within 60 days prior to study drug
             administration.

          -  Use of more than two AEDs, or a change in antiepileptic medication within 30 days
             prior to study drug administration.

          -  Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies
             (anti-HCV) or Human Immunodeficiency Virus (HIV) antibodies.

          -  Positive screen for alcohol and/or drugs of abuse (including barbiturates, opiates,
             cocaine, cannabinoids, amphetamines and benzodiazepines). Note: Patients who currently
             take phenobarbital, mysoline or primidone as antiepileptic therapy and test positive
             for barbiturates are eligible for study participation. Patients who currently take
             vigabatrin or frisium as antiepileptic therapy and test positive for benzodiazepines
             are eligible for study participation.

          -  Recent history (within previous 6 months) of alcohol or drug abuse.

          -  Drinks, on average, more than 5 cups of tea/coffee/cocoa/cola per day.

          -  Smokes on average more than 10 cigarettes per day.

          -  Clinically significant acute illness within 7 days prior to study drug administration.

          -  Plasma donation within 7 days prior to study drug administration.

          -  Legal incapacity or limited legal capacity.

          -  Likely, in the investigator's opinion, not to cooperate with, or to respect the
             constraints of the study.

          -  Donation of 1 or more units (approximately 450 mL) of blood or acute loss of an
             equivalent amount of blood within 90 days prior to study drug administration.

          -  Have received an experimental drug or used an experimental medical device within 90
             days before the planned start of treatment and/ or plan to use during the planned
             study participation.

          -  Employees of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator.

          -  Patients taking concomitant medications metabolized by CYP2C19 and/or CYP2B6.